| Simultaneous targeted and discovery-driven clinical proteotyping using hybrid-PRM/DIA S Goetze, A van Drogen, JB Albinus, KL Fort, T Gandhi, D Robbiani, ... Clinical Proteomics 21 (1), 26, 2024 | | 2024 |
| Probabilistic pathway-based multimodal factor analysis A Immer, SG Stark, F Jacob, X Bonilla, T Thomas, A Kahles, S Goetze, ... Bioinformatics 40 (Supplement_1), i189-i198, 2024 | | 2024 |
| Proteomic profiling of advanced melanoma patients to predict therapeutic response to anti-PD-1 therapy N Zila, OM Eichhoff, I Steiner, T Mohr, A Bileck, PF Cheng, A Leitner, ... Clinical Cancer Research 30 (1), 159-175, 2024 | 1 | 2024 |
| Multiomics Profiling Reveals Higher RNA Isoform Diversity and Potential Oncospecific Protein Isoform Targets in HSPCs of MDS and MDS/MPN Patients N Bonadies, V Grigorjev, N Porret, K Harshman, LL Grob, TN Rao, ... Blood 142, 4592, 2023 | | 2023 |
| SINGLE-CELL FUNCTIONAL TISSUE PROFILING IDENTIFIES PROMISING CANDIDATES FOR DRUG REPURPOSING AGAINST GLIOBLASTOMA T Weiss, S Lee, M Buehler, J Mena, Z Lottenbach, R Wegmann, M Bihl, ... NEURO-ONCOLOGY 25, 2023 | | 2023 |
| Proteogenetic drug response profiling elucidates targetable vulnerabilities of myelofibrosis MHE Wildschut, J Mena, C Dördelmann, M van Oostrum, BD Hale, ... Nature Communications 14 (1), 6414, 2023 | 2 | 2023 |
| # 174 Integrated multi-omic and clinicopathological analysis of vulvar squamous cell carcinoma: identification of predictive biomarkers for personalized treatment TA Zwimpfer, F Lombardo, N Rimmer, S Götze, F Singer, A Bertolini, ... International Journal of Gynecologic Cancer 33 (Suppl 3), 2023 | | 2023 |
| Mapping the dynamic high-density lipoprotein synapse K Frey, L Rohrer, F Frommelt, M Ringwald, A Potapenko, S Goetze, ... Atherosclerosis 380, 117200, 2023 | | 2023 |
| Ex vivo drug response heterogeneity reveals personalized therapeutic strategies for patients with multiple myeloma K Kropivsek, P Kachel, S Goetze, R Wegmann, Y Festl, Y Severin, ... Nature Cancer 4 (5), 734-753, 2023 | 14 | 2023 |
| ROS induction targets persister cancer cells with low metabolic activity in NRAS-mutated melanoma OM Eichhoff, CI Stoffel, J Käsler, L Briker, P Turko, G Karsai, N Zila, ... Cancer Research 83 (7), 1128-1146, 2023 | 9 | 2023 |
| Standardization of suspension and imaging mass cytometry readouts for clinical decision making R Casanova, S Xu, S Sivapatham, A Jacobs, S Engler, ... bioRxiv, 2023.03. 19.531228, 2023 | | 2023 |
| Mapping the dynamic cell surface interactome of high-density lipoprotein reveals Aminopeptidase N as modulator of its endothelial uptake K Frey, L Rohrer, A Potapenko, S Goetze, A von Eckardstein, ... bioRxiv, 2023.01. 03.522574, 2023 | 1 | 2023 |
| Integrated multi-omics reveals anaplerotic rewiring in methylmalonyl-CoA mutase deficiency P Forny, X Bonilla, D Lamparter, W Shao, T Plessl, C Frei, A Bingisser, ... Nature Metabolism 5 (1), 80-95, 2023 | 13 | 2023 |
| Detection of isoforms and genomic alterations by high-throughput full-length single-cell RNA sequencing for personalized oncology A Dondi, U Lischetti, F Jacob, F Singer, N Borgsmüller, ... bioRxiv, 2022.12. 12.520051, 2022 | 5 | 2022 |
| Use of MS-GUIDE for identification of protein biomarkers for risk stratification of patients with prostate cancer S Goetze, P Schüffler, A Athanasiou, A Koetemann, C Poyet, ... Clinical Proteomics 19 (1), 9, 2022 | 5 | 2022 |
| ROS induction as a strategy to target persister cancer cells with low metabolic activity in NRAS mutated melanoma OM Eichhoff, CI Stoffel, J Käsler, L Briker, P Turko, G Karsai, N Zila, ... bioRxiv, 2022.10. 19.512839, 2022 | | 2022 |
| Targeting tumour-intrinsic neural vulnerabilities of glioblastoma S Lee, T Weiss, M Bühler, J Mena, Z Lottenbach, R Wegmann, M Bihl, ... bioRxiv, 2022.10. 07.511321, 2022 | 2 | 2022 |
| ROS induction as a strategy to target persister cancer cell metabolism O Eichhoff, C Stoffel, L Briker, P Turko, G Karsai, V Paulitschke, ... European Journal of Cancer 174, S3, 2022 | | 2022 |
| Decoding functional high-density lipoprotein particle surfaceome interactions K Frey, S Goetze, L Rohrer, A von Eckardstein, B Wollscheid International Journal of Molecular Sciences 23 (16), 9506, 2022 | 5 | 2022 |
| Image-based functional precision medicine for repurposing neuroactive drugs in glioblastoma S Lee, T Weiss, M Bühler, R Wegmann, J Mena, M Bihl, S Goetze, ... Cancer Research 82 (12_Supplement), 5325-5325, 2022 | | 2022 |
Bernd WollscheidETH Zurich, Department of Health Sciences and Technology在 ethz.ch 的电子邮件经过验证
